Literature DB >> 8294559

A potential role for human herpesvirus type 6 in nervous system disease.

F Wilborn1, C A Schmidt, V Brinkmann, K Jendroska, H Oettle, W Siegert.   

Abstract

Human herpesvirus type 6 (HHV-6) is a new representative of the herpesvirus family which was associated with a spectrum of diseases, including myalgic encephalitis, meningitis and the chronic fatigue syndrome. We set out to study the potential role of HHV-6 in multiple sclerosis (MS) (n = 21), facial palsy (FP) (n = 19) and Guillain-Barré-syndrome (GBS) (n = 7). Results were compared with a control group (CG) (n = 16). We analyzed paired samples of serum and cerebrospinal fluid (CSF) with the polymerase chain reaction (PCR) for the presence of HHV-6 DNA. The studies were complemented by ELISA determination of serum antibodies against HHV-6. In the MS group we detected HHV-6 DNA in the CSF from three of 21 (14.3%) patients but not in the corresponding serum samples. In FP, GBS and controls CSF and serum PCRs were negative in all cases. HHV-6 serum antibody titers were significantly higher in MS compared with FP, GBS and controls. These findings suggest that HHV-6 may play a role in MS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294559     DOI: 10.1016/0165-5728(94)90198-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

Review 2.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

3.  Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Authors:  J Lycke; B Svennerholm; E Hjelmquist; L Frisén; G Badr; M Andersson; A Vahlne; O Andersen
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 4.  Human herpesvirus-6 infections.

Authors:  C A Jones; D Isaacs
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

5.  Presumptive human herpesvirus 6 myelopathy in an immunocompetent patient.

Authors:  Roger E Kelley; Joseph R Berger; Mary Espey; Brian P Kelley
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

6.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls.

Authors:  M Enbom; F Z Wang; S Fredrikson; C Martin; H Dahl; A Linde
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 8.  Update on human herpesvirus 6 biology, clinical features, and therapy.

Authors:  Leen De Bolle; Lieve Naesens; Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

9.  Varicella-zoster virus at relapses of multiple sclerosis.

Authors:  Julio Sotelo; Graciela Ordoñez; Benjamin Pineda
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

10.  Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression.

Authors:  Rossana Berti; Meghan B Brennan; Samantha S Soldan; Joan M Ohayon; Luca Casareto; Henry F McFarland; Steven Jacobson
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.